Indication
Denosumab (Prolia) is given to reduce the risk of osteoporotic fractures in post-menopausal women and men. Denosumab is an amber drug (3 months) and must be given in accordance with the BNSSG shared care guidance [accessed 27/09/2019]
https://remedy.bnssgccg.nhs.uk/media/3288/denosumab-scp-2018.pdf